Key result
Preoperative aspirin therapy reduced the risk of 30-day mortality compared to no aspirin in patients undergoing cardiac surgery.
Why the study?
Does preoperative aspirin use reduce major cardiocerebral complications and 30-day mortality in patients undergoing cardiac surgery?
Cohort (n=2,868)
Yes
Does preoperative aspirin use reduce major cardiocerebral complications and 30-day mortality in patients undergoing cardiac surgery?
Preoperative aspirin use within 5 days of cardiac surgery is associated with reduced 30-day mortality, renal failure, and major adverse cardiocerebral events.
Answers are grounded in this paper and cite their sources.
Does not support changing preoperative aspirin protocols; leaves open confirmation of mortality benefit in randomized trials.
BACKGROUND: The effects of preoperative aspirin use on outcomes of cardiac surgery patients remain uncertain. This study was aimed to evaluate the effect of preoperative aspirin use on major outcomes in cardiac surgery patients. METHODS: An observational cohort study was performed on consecutive patients (n = 4256) undergoing cardiac surgery in 2 tertiary hospitals. Of all patients, 2868 patients met the inclusion criteria and were divided into 2 groups: those taking (n = 1923) or not taking (n = 945) aspirin within 5 days preceding surgery. RESULTS: Patients in the aspirin group presented significantly more with comorbidities including hypertension, diabetes, peripheral arterial disease, previous myocardial infarction, angina, cerebrovascular disease, older age, and male gender. With propensity scores adjusted and multivariate logistic regression, however, the results of this study showed that preoperative aspirin therapy (vs nonaspirin) significantly reduced the risk of 30-day mortality (3.5% vs 6.5%, OR: 0.611, 95% CI: 0.391-0.956, P = 0.031), postoperative renal failure (3.7% vs 7.1%, OR: 0.384, 95% CI: 0.254-0.579, P < 0.001), dialysis required (1.9% vs 3.6%, OR: 0.441, 95% CI: 0.254-0.579, P < 0.001), intensive care unit stay (mean 107.2 vs 136.1 h, P < 0.001) and a composite outcome-major adverse cardiocerebral events (8.7% vs 10.8%, OR: 0.662, 95% CI:: 0.482-0.909, P = 0.011) in the patients undergoing cardiac surgery. However, readmissions did not show a significant difference between the 2 groups (14.5% vs 12.8%, P = 0.944). CONCLUSIONS: Preoperative aspirin therapy is associated with a significant decrease in the risk of major cardiocerebral complications, renal failure, intensive care unit stay and 30-day mortality but does not increase the risk of readmissions in patients undergoing cardiac surgery.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2011) conducted a cohort in Cardiac surgery (n=2,868). Preoperative aspirin vs. No preoperative aspirin was evaluated on 30-day all-cause mortality (OR 0.611, 95% CI 0.391-0.956, p=0.031). Preoperative aspirin therapy reduced the risk of 30-day mortality compared to no aspirin in patients undergoing cardiac surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: